drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T-cell)
drug_description
An autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy in which patient T cells are genetically modified to express a CAR targeting CD19, leading to T-cell activation, proliferation, cytokine release, and cytolysis of CD19+ B cells when infused intravenously.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor; upon binding CD19 on B cells, CAR signaling (CD3 zeta with co-stimulatory domains) activates the T cells, inducing proliferation, cytokine release, and cytolytic killing of CD19-positive malignant and normal B cells.
drug_name
L218CAR19
nct_id_drug_ref
NCT06478381